CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
Phase 1
Recruiting
- Conditions
- Rotavirus Infections
- Interventions
- Biological: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)Biological: 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)Other: Placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 50
- Registration Number
- NCT06962904
- Locations
- 🇺🇸
Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia, United States
Efficacy of Flow Restrictors in Limiting Access of Liquid Medicines by Young Children
Not Applicable
Completed
- Conditions
- Enhanced Child-safety Packaging
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 120
- Registration Number
- NCT06938620
CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults
Phase 1
Active, not recruiting
- Conditions
- Rotavirus Infections
- Interventions
- Biological: 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)Biological: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)Other: Placebo
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 50
- Registration Number
- NCT06485258
- Locations
- 🇺🇸
Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia, United States
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia
Phase 4
Completed
- Conditions
- MalariaPlasmodium FalciparumUncomplicated Malaria
- Interventions
- Drug: Amodiaquine-artesunate (ASAQ)Drug: Artemether+Lumefantrine (AL)
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 352
- Registration Number
- NCT06300970
- Locations
- 🇱🇷
Sinje Health Center, Garwula District, Sinje, Grand Cape Mount County, Sinje, Grand Cape Mount County, Liberia
🇱🇷Saclepea-Mahn Comprehensive Health Center Saclepea-Mahn District, Nimba County, Saclepea, Nimba County, Liberia
Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP
Phase 3
Active, not recruiting
- Conditions
- Influenza
- Interventions
- Biological: FluQuadri
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 192
- Registration Number
- NCT06054269
- Locations
- 🇵🇪
Hospital Nacional Arzobispo Loayza, Lima, Peru
🇵🇪Hospital Nacional Cayetano Heredia, Lima, Peru
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Recruiting
- Conditions
- MonkeypoxAIDSHIV Infections
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 100
- Registration Number
- NCT06045923
- Locations
- 🇺🇸
Centers for Disease Control and Prevention, Atlanta, Georgia, United States
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Phase 2
Recruiting
- Conditions
- Tuberculosis, PulmonaryTuberculosis Infection
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
🇺🇸TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine
Phase 4
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBPBiological: Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMSBiological: Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBPBiological: Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1224
- Registration Number
- NCT05460377
- Locations
- 🇧🇩
Icddr,B Study Clinics, Dhaka, Bangladesh
Immunogenicity nOPV2 With and Without bOPV
Phase 2
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Novel monovalent oral poliovirus vaccine type 2 (nOPV2)Biological: Bivalent oral poliovirus vaccine (bOPV)
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 795
- Registration Number
- NCT04579510
- Locations
- 🇧🇩
Icddr,B Study Clinics, Dhaka, Bangladesh
Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: VaxigripTetra™ by Sanofi, Inc.Biological: Flublok™ Quadrivalent by Sanofi, Inc.
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 577
- Registration Number
- NCT04523324
- Locations
- 🇮🇱
Soroka Medical Center, Be'er Sheva, Israel
🇮🇱Rabin Medical Center-Beilinson, Petah Tikva, Israel